A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease
Milton H. Werner(Inhibikase Therapeutics (United States)), Aaron Ellenbogen, Andrew McGarry(Cooper Medical School of Rowan University), Beth Safirstein(Velocity Clinical Research (United States)), Lawrence F. Blob(Cognitive Research (United States)), C. Warren Olanow(Icahn School of Medicine at Mount Sinai), Shannon Walaker(Cognitive Research (United States)), C. Meyer(Inhibikase Therapeutics (United States)), Carlos Rodríguez, Emil Samara, Howard Hassman, Larry Ereshefsky(The University of Texas at San Antonio Health Science Center), Sydney Kruger(Inhibikase Therapeutics (United States)), Jacqueline Pellecchia(Inhibikase Therapeutics (United States))
Cited by 7
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
|New England Journal of Medicine|2009|889
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
|The Lancet Neurology|2015|508